The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience
- Авторлар: Protsenko S.A.1, Teletaeva G.M1, Latipova D.K.1, Semenova A.I1, Novik A.V1, Komarov Y.I1, Dzhalilova S.A1, Malygin A.Y.1, Degtiareva E.A1
-
Мекемелер:
- N.N. Petrov National Research Center of Oncology
- Шығарылым: Том 29, № 7 (2022)
- Беттер: 53-56
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321028
- DOI: https://doi.org/10.18565/pharmateca.2022.7.53-56
- ID: 321028
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
Авторлар туралы
Svetlana Protsenko
N.N. Petrov National Research Center of Oncology
Email: s.protsenko@list.ru
Dr. Sci. (Med.), Prof., Head of the Department of Chemotherapy and Innovative Technologies St. Petersburg, Russia
G. Teletaeva
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
D. Latipova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. Semenova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. Novik
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
Yu. Komarov
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
Sh. Dzhalilova
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
A. Malygin
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
E. Degtiareva
N.N. Petrov National Research Center of OncologySt. Petersburg, Russia
Әдебиет тізімі
- Каприн А.Д., Старинский В.В., Петрова ГВ. Состояние онкологической помощи населению России в 2017 году. М., 2018. 236 с.
- Hoang N.T., Acevedo L.A., Mann M.J., Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089-114. doi: 10.2147/CMAR.S159641.
- Seetharam M., Kolla K.R., Chawla S.P Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies. Clin Oncol. 2018;3:1426.
- Frezza A.M., Stacchiotti S., Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109. doi: 10.1186/s12916-017-0872-y.
- Miyamoto S., Kakutani S., Sato Y, et al. Drug review: Pazopanib. Jpn J Clin Oncol. 2018;48(6):503-13. doi: 10.1093/jjco/hyy053.
- Lee A.T.J., Jones R.L., Huang P.H. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;17;4:16. doi: 10.1038/s41392-019-0049-6.
- FDA approves Votrient for advanced soft tissue sarcoma. URL: https://www.drugs.com/newdrugs/fda-approves-votrient-advanced-soft-tissue-sarcoma-3199.html
- Podar K., Tonon G., Sattler M., et al. The molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51):19478-83. doi: 10.1073/pnas.0609329103.
- Glade Bender J.L., Lee A., Reid J.M., et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914.
- Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223.
- Van der Graaf W.T., Blay J.Y, Chawla S.P, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5.